Corvus Pharmaceuticals (NASDAQ:CRVS) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday, February 2nd.
Separately, Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $20.25.
Shares of Corvus Pharmaceuticals (CRVS) opened at $8.12 on Friday. The company has a market cap of $171.49, a P/E ratio of -3.05 and a beta of -2.39. Corvus Pharmaceuticals has a 12 month low of $7.54 and a 12 month high of $22.14.
In other news, CEO Richard A. Md Miller bought 10,000 shares of the stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $10.79 per share, with a total value of $107,900.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 46.40% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System boosted its holdings in shares of Corvus Pharmaceuticals by 121.2% in the 2nd quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock valued at $181,000 after purchasing an additional 8,200 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Corvus Pharmaceuticals by 2,269.1% in the 2nd quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after purchasing an additional 9,099 shares during the last quarter. State Street Corp boosted its holdings in shares of Corvus Pharmaceuticals by 18.6% in the 2nd quarter. State Street Corp now owns 62,475 shares of the company’s stock valued at $756,000 after purchasing an additional 9,779 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Corvus Pharmaceuticals by 118.1% in the 4th quarter. Deutsche Bank AG now owns 19,058 shares of the company’s stock valued at $196,000 after purchasing an additional 10,320 shares during the last quarter. Finally, Teachers Advisors LLC boosted its holdings in shares of Corvus Pharmaceuticals by 338.4% in the 2nd quarter. Teachers Advisors LLC now owns 15,568 shares of the company’s stock valued at $188,000 after purchasing an additional 12,017 shares during the last quarter. Institutional investors own 81.05% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/17/corvus-pharmaceuticals-crvs-downgraded-by-valuengine.html.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.